(Q38298318)

1 September 2017

title

Antitumor activity of 4-(N-hydroxyphenyl)retinamide conjugated with poly(L-glutamic acid) against ovarian cancer xenografts (English)

1 reference

1 September 2017

1 reference

1 reference

Changping Zou

1

1 reference

1 September 2017

Molly Brewer

2

1 reference

1 September 2017

Xianyi Cao

3

1 reference

1 September 2017

Rongyu Zang

4

1 reference

1 September 2017

Jianxin Lin

5

1 reference

1 September 2017

Yuanjian Deng

6

1 reference

1 September 2017

Chun Li

7

1 reference

1 September 2017

language of work or name

English

0 references

publication date

14 September 2007

1 reference

1 September 2017

1 reference

1 September 2017

volume

107

1 reference

1 September 2017

issue

3

1 reference

1 September 2017

page(s)

441-449

1 reference

1 September 2017

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Signaling pathways in retinoid chemoprevention and treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Fenretinide and its relation to cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Phase II trial of fenretinide in advanced renal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Poly(L-glutamic acid)--anticancer drug conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Contrast-enhanced sonography helps in discrimination of benign from malignant adnexal masses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Pilot study of high dose fenretinide and vitamin A supplementation in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Retinoids and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Mechanism of fenretinide (4-HPR)-induced cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Effect of fenretinide on ovarian carcinoma occurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

13-cis-retinoic acid in the treatment of oral leukoplakia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

13-cis-Retinoic Acid Plus Interferon -2a: Highly Active Systemic Theraphy for Squamous Cell Carcinoma of the Cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Prevention of Recurrent Superficial Bladder Tumors by Oral Etretinate: Preliminary Results of a Randomized, Double Blind Multicenter Trial in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

Retinoids and chemoprevention: clinical and basic studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.077

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2007.07.077

1 reference

1 September 2017

1 reference